WASHINGTON, April 25, 2026 —
Key Takeaways
- More than 2.6 million Medicare Advantage enrollees — roughly 13% of all individual plan members — had their coverage terminated at the end of 2025 as insurers exited markets or discontinued plans, the highest termination rate in the program’s history.
- The number of Medicare Advantage plans available to the average beneficiary dropped from a peak of 36 plans in 2024 to 32 plans in 2026, reversing years of expansion as insurers pull back from a program they say is no longer profitable enough to sustain.
- A new $2,100 hard cap on out-of-pocket drug spending under Part D takes effect this year — one of the most significant prescription drug cost protections ever added to Medicare — yet surveys suggest fewer than 1 in 3 beneficiaries are aware it applies to their plan.
Why Are Medicare Advantage Plans Cutting Benefits Right Now?
Medicare Advantage — the private-insurance alternative to original Medicare that now covers more than 34 million Americans, or 54% of all Medicare-eligible adults — spent the last decade expanding aggressively. Plans competed by piling on extras: dental, vision, hearing aids, gym memberships, meal delivery, over-the-counter allowances. Enrollment surged. Premiums stayed low. It looked like a system working exactly as designed.
The math has now caught up with the marketing.
Medical costs inside Medicare Advantage plans rose sharply in 2024 and 2025, driven by a post-pandemic surge in elective procedures, higher hospital utilization, and the growing complexity of an aging enrollee population. At the same time, the federal government adjusted how it pays insurers — reducing the rebate-based payments that plans had been using to fund those extra benefits. The result: insurers began cutting the extras, exiting unprofitable counties, and terminating plans entirely.
In 2025, plan terminations affected 13% of individual Medicare Advantage enrollees — more than double the 6% rate the year before. Most of those 2.6 million displaced beneficiaries found another plan. But switching plans mid-retirement is not a neutral event. It can mean losing your doctor, changing your pharmacy, losing benefits you had counted on, and starting over on a new plan’s prior authorization requirements.
What Specifically Got Cut — and What Got Better
| Benefit Category | 2025 Status | 2026 Status | Direction |
|---|---|---|---|
| Average MA-PD monthly premium | $13.32 | $11.50 | ✅ Lower |
| Max out-of-pocket (in-network) | $9,350 | $9,250 | ✅ Slightly lower |
| Part D out-of-pocket drug cap | None (catastrophic phase) | $2,100 hard cap | ✅ Major win |
| Insulin cost-sharing | Varies by plan | Capped — no deductible | ✅ Major win |
| Plans offering OTC allowances | Higher % | Declining | ❌ Cut |
| Plans offering post-hospital meals | Widely available | Fewer plans | ❌ Cut |
| Supplemental benefits (chronically ill) | Broad | Restricted by CMS rule | ❌ Cut |
| Available plans per beneficiary | 36 peak | 32 | ❌ Fewer options |
| Plans terminated end of 2025 | — | 2.6M enrollees affected | ❌ Record high |
The Drug Cap Is the Biggest Change Most People Are Missing
Starting January 1, 2026, Medicare Part D — the prescription drug component of Medicare, available either standalone or bundled into most Medicare Advantage plans — now carries a hard $2,100 out-of-pocket spending cap. Once a beneficiary has spent $2,100 on covered drugs in a calendar year, their cost-sharing drops to zero for the remainder of the year.
This is a structural change, not a plan-by-plan option. It applies across all Part D coverage. For the roughly 3.6 million Medicare beneficiaries who previously hit the catastrophic spending threshold — often people managing cancer, multiple sclerosis, rheumatoid arthritis, or other high-cost chronic conditions — this cap can mean thousands of dollars in annual savings.
Insulin is separately protected. Under the 2026 final rule from the Centers for Medicare & Medicaid Services, insulin cost-sharing is capped and no Part D deductible applies to insulin purchases. For the approximately 3.4 million Medicare beneficiaries with diabetes who use insulin, this removes a financial barrier that caused measurable rates of rationing and skipped doses in prior years.
The Part D deductible itself increased slightly — to $615 in 2026, up from $590 in 2025 — meaning the first dollars spent on drugs cost a little more before coverage kicks in. The net effect for most beneficiaries still comes out positive once the $2,100 cap is applied.
More Than 7 Million Chronically Ill Seniors Lost Supplemental Benefits
This is the number that hasn’t received enough attention. The Centers for Medicare & Medicaid Services tightened the definition of allowable supplemental benefits under the Special Supplemental Benefits for the Chronically Ill program — a category that had allowed Medicare Advantage plans to offer non-medical benefits, like home modifications, pest control, and certain food allowances, to members with persistent conditions.
The 2026 rule codified a list of benefits that no longer qualify — including certain cosmetic procedures, services without a direct link to health maintenance, and items that CMS determined did not meet the standard of “reasonable expectation of improving or maintaining health or function.” More than 7 million enrollees in Medicare Advantage plans, many of them chronically ill and low-income, lost access to at least some of these extras as a result.
For a homebound senior who had been receiving $100 a month in grocery allowances through a Medicare Advantage supplemental benefit, losing that benefit is not a minor administrative change. It is a direct reduction in monthly income at the most financially vulnerable period of their life.
[Internal link → “Health” category page] on chronically ill seniors.
The Prior Authorization Problem Is Getting Worse, Not Better
Prior authorization — the requirement that doctors get insurer approval before delivering certain treatments — has been a flashpoint in Medicare Advantage for years. Lawmakers, physicians, and patient advocates have documented cases where prior authorization delays led to deteriorating health, hospital admissions, and in documented cases, patient deaths.
CMS launched a new AI-assisted prior authorization pilot program in 2026, covering at least 16 devices and procedures identified as particularly vulnerable to fraud and overuse. The program pays technology vendors based on savings from denied claims — a structure that the American Medical Association has called a direct conflict of interest, arguing it creates financial incentives for the AI to deny coverage regardless of medical necessity.
The pilot is live. Its outcomes are not yet publicly tracked in real time. The AMA and several patient advocacy organizations have demanded CMS publish denial rate data and appeals outcomes before expanding the program. That data has not been released.
[AD UNIT — optional second placement for desktop long-form]
Pro Tips a Generic Article Would Miss
1. The $2,100 Part D drug cap resets every January 1 — and your retirement income planning should account for it. For seniors managing high-cost conditions, this cap creates a predictable annual ceiling on drug spending that did not exist before. Build your tax-advantaged savings and HSA withdrawal strategy around this number: you now know the worst-case out-of-pocket drug scenario, which makes healthcare budgeting in retirement significantly more precise.
2. If your plan was terminated and you switched, check whether your new plan’s prior authorization rules cover your existing treatments. Switching Medicare Advantage plans — even to another plan from the same insurer — does not guarantee continuity of prior authorization approvals. A treatment approved under your old plan may require a new prior authorization under the new one, and the review process can take weeks. Request written confirmation before your first claim is submitted.
3. Nearly one-third of Medicare Advantage plans now offer a Part B premium reduction as a supplemental benefit — and most enrollees never check if theirs does. Among plans offering this reduction, more than a third reduce the Part B premium by over $100 a month. At $202.90 per month for standard Part B in 2026, a $100 reduction translates to $1,200 per year in retained retirement income. This is the kind of 401(k) diversification equivalent that exists inside your health plan — real money left on the table because most people never open the supplemental benefits guide.
The most concrete action any Medicare Advantage enrollee can take right now is a ten-minute benefits audit. Pull up your 2026 Evidence of Coverage document — mailed to you in October, downloadable from your plan’s website — and check three things: whether your current doctors are still in-network under your plan’s updated 2026 directory, whether you have hit or are approaching the $2,100 Part D drug cap, and whether your plan offers a Part B premium reduction you are not using. If your plan was terminated in 2025 and you were auto-enrolled in a replacement, those answers may be different from what you expect.
Frequently Asked Questions
Q: Is Medicare Advantage being cancelled in 2026? A: No. Medicare Advantage remains available and covers more than 34 million Americans. However, 2.6 million enrollees had their specific plans terminated at the end of 2025, the highest rate on record. Most found replacement coverage, but benefits and networks may have changed.
Q: What is the new Medicare Part D out-of-pocket cap for 2026? A: Starting in 2026, once you spend $2,100 out-of-pocket on covered Part D drugs in a calendar year, your cost-sharing drops to zero for the rest of the year. This is a hard cap that applies to all Part D plans — it is not optional or plan-specific.
Q: Why did my Medicare Advantage supplemental benefits get cut in 2026? A: CMS tightened the definition of allowable supplemental benefits for chronically ill enrollees, removing coverage for items and services it determined did not meet health-maintenance standards. More than 7 million beneficiaries were affected by these reductions.
Q: Is insulin free under Medicare in 2026? A: Not free, but capped. Under the 2026 final rule, insulin cost-sharing is capped at the lower of 25% of the negotiated price or 25% of the maximum fair price established under the Medicare Drug Price Negotiation Program — and no Part D deductible applies to insulin purchases.
Q: Should I switch from Medicare Advantage to original Medicare in 2026? A: It depends entirely on your health needs, income, and providers. Medicare Advantage offers lower premiums and extra benefits but comes with network restrictions and prior authorization requirements. Original Medicare offers broader provider access but requires separate Medigap and Part D coverage for comprehensive protection. A licensed Medicare counselor — available free through your State Health Insurance Assistance Program — can model both options for your specific situation.
